Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia
Tagraxofusp in Patients With CD123+ or With Blastic Plasmacytoid Dendritic Cell Neoplasm Immunophenotype-like Acute Myeloid Leukemia
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Terminated
poor enrollment
Other terminated trials from Gruppo Italiano Malattie EMatologiche dell'Adulto
- Chronic Lymphoid Leukemia · Phase PHASE2 · May 2024
- Adults · Phase PHASE2 · Dec 2022
- Acute Lymphoblastic Leukemia · Phase PHASE2 · Dec 2021
- Acute Myeloid Leukemia · Jun 2020
- AML · May 2019
See all terminations from Gruppo Italiano Malattie EMatologiche dell'Adulto
Other Acute Myeloid Leukemia trials with similar outcome
This PHASE2 trial investigates Acute Myeloid Leukemia and is currently terminated or withdrawn. Gruppo Italiano Malattie EMatologiche dell'Adulto leads this study, which shows 8 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Feb 2025 — Sep 2025 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Feb 2022 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 3 earlier versions
-
Jan 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
May 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Gruppo Italiano Malattie EMatologiche dell'Adulto
For direct contact, visit the study record on ClinicalTrials.gov .